Image-Guided Radiotherapy Dose Escalation in Intermediate and High Risk Cancer Prostate Patients and Its Effect on Treatment Toxicity — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Image-Guided Radiotherapy Dose Escalation in Intermediate and High Risk Cancer Prostate Patients and Its Effect on Treatment Toxicity
Department of Radiation Oncology, NCI-Cairo University, Cairo, Egypt
,
Department of Radiation Oncology, NCI-Cairo University, Cairo, Egypt
,
Department of Radio Diagnosis, NCI-Cairo University, Cairo, Egypt
,
Department of Medical Oncology, NCI-Cairo University, Cairo, Egypt
,
Department of Radiation Oncology, NCI-Cairo University, Cairo, Egypt
,
Department of Medical Statistics, NCI-Cairo University, Cairo, Egypt
,
Department of Radiation Oncology, NCI-Cairo University, Cairo, Egypt
1 Department of Radiation Oncology, NCI-Cairo University, Cairo, Egypt
2 Department of Radiation Oncology, NCI-Cairo University, Cairo, Egypt
3 Department of Radio Diagnosis, NCI-Cairo University, Cairo, Egypt
4 Department of Medical Oncology, NCI-Cairo University, Cairo, Egypt
5 Department of Radiation Oncology, NCI-Cairo University, Cairo, Egypt
6 Department of Medical Statistics, NCI-Cairo University, Cairo, Egypt
7 Department of Radiation Oncology, NCI-Cairo University, Cairo, Egypt
Purpose: To study the effect of escalating radiation dose; in intermediate and high risk prostate cancer patients; via online image-guidance on acute toxicities. Patients and Methods: thirty-eight prostate cancer patients were treated by using simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT) with online image guided correction via kilo voltage cone beam computed tomography (KV-CBCT)/electronic portal imaging device (EPID) of trans-rectal ultrasound (TRUS)-inserted intraprostatic gold fiduciary markers. High-risk patients received a median dose of 80.5 Gy to prostate and 56 Gy to pelvic nodes in 35 fractions over 7 weeks. Intermediate-risk patients received a similar prostate dose over the same overall treatment time. Acute toxicity (bladder, rectal and bowel symptoms) was reported once weekly during the radiation course and up to 3 months from the end of the radiation course. Results: The image guided (IG)-IMRT allows escalating the radiation dose delivered to the prostate through minimizing the margin of setup error to less than 0.5 cm with subsequent sparing of nearby organs at risk. Out of thirty-eight patients, no patient developed >grade 1 acute rectal toxicity, 7.9% of patients experienced grade 3 urinary toxicity and there was no reported small intestinal toxicity. Conclusion: Escalating the radiation dose more than 80 Gy in intermediate and high risk prostate cancer patients was safe and not associated with grade 3 - 4 RTOG toxicity when guided by online verification of intra-prostatic fiducial markers.
Crook, J.M., Raymond, Y., Salhani, D., et al. (1995) Prostate Motion during Standard Radiotherapy as Assessed by Fiducial Markers. Radiotherapy and Oncology, 37, 35-42. https://doi.org/10.1016/0167-8140(95)01613-L
Ghilezan, M.J., Jaffray, D.A., Siewerdsen, J.H., et al. (2005) Prostate Gland Motion Assessed with Cine-Magnetic Resonance Imaging (Cine-MRI). International Journal of Radiation Oncology, Biology, Physics, 62, 406-417. https://doi.org/10.1016/j.ijrobp.2003.10.017
Balter, J.M., Kwok, L.L., Sandler, H.M., et al. (1995) Automated Localization of the Prostate at the Time of Treatment Using Implanted Radiopaque Markers: Technical Feasibility. International Journal of Radiation Oncology, Biology, Physics, 33, 1281. https://doi.org/10.1016/0360-3016(95)02083-7
Balter, J.M., Lam, K.L., Sandler, H.M., et al. (1994) Automated Tracking of Prostate Position Using On-Line Portal Imaging. Medical Physics, 21, 951.
Balter, J.M., Sandler, H.M., Lam, K., et al. (1995) Measurement of Prostate Movement over the Course of Routine Radiotherapy Using Implanted Markers. International Journal of Radiation Oncology, Biology, Physics, 31, 113-118. https://doi.org/10.1016/0360-3016(94)00382-U
Chung, P.W., Haycocks, T., Brown, T., et al. (2004) On-Line Portal Imaging of Implanted Fiducial Markers for the Reduction of Interfraction Error during Conformal Radiotherapy of Prostate Carcinoma. International Journal of Radiation Oncology, Biology, Physics, 60, 329-334. https://doi.org/10.1016/j.ijrobp.2004.03.038
Nederveen, A., Lagendijk, J., Hofman, P., et al. (2000) Detection of Fiducial Gold Markers for Automatic On-Line Megavoltage Position Verification Using a Marker Extraction Kernel (MEK). International Journal of Radiation Oncology, Biology, Physics, 47, 1435-1442. https://doi.org/10.1016/S0360-3016(00)00523-X
Vigneault, E., Pouliot, J., Laverdiere, J., et al. (1997) Electronic Portal Imaging Device Detection of Radioopaque Markers for the Evaluation of Prostate Position during Megavoltage Irradiation: A Clinical Study. International Journal of Radiation Oncology, Biology, Physics, 37, 205-212. https://doi.org/10.1016/S0360-3016(96)00341-0
Nichol, A.M., Brock, K.K., Lockwood, G.A., et al. (2007) A Magnetic Esonance Imaging Study of Prostate Deformation Relative to Implanted Gold Fiducial Markers. International Journal of Radiation Oncology, Biology, Physics, 67, 48-239. https://doi.org/10.1016/j.ijrobp.2006.08.021
D’Amico, A.V., Whittington, R., Malkowicz, S.B., et al. (1999) Pretreatment Nomogram for Prostate-Specific Antigen Recurrence after Radical Prostatectomy or External-Beam Radiation Therapy for Clinically Localized Prostate Cancer. Journal of Clinical Oncology, 17, 168-172. https://doi.org/10.1200/JCO.1999.17.1.168
Crook, J., Ots, A.F., et al. (2013) Prognostic Factors for Newly Diagnosed Prostate Cancer and Their Role in Treatment Selection. Seminars in Radiation Oncology, 23, 165-172. https://doi.org/10.1016/j.semradonc.2013.01.002
Cooperberg, M.R., Broering, J.M., Carroll, P.R., et al. (2010) Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 28, 1117-1123. https://doi.org/10.1200/JCO.2009.26.0133
Beckendorf, V., Guerif, S., Le Prise, E., et al. (2011) 70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of Getug 06 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 80, 1056-1063. https://doi.org/10.1016/j.ijrobp.2010.03.049
Dearnaley, D.P., Sydes, M.R., Graham, J.D., et al. (2007) Escalated-Dose Versus Standard-Dose Conformal Radiotherapy in Prostate Cancer: First Results from the MRC RT01 Randomised Controlled Trial. Lancet Oncology, 8, 475-487. https://doi.org/10.1016/S1470-2045(07)70143-2
Ohri, N., Dicker, A.P., Showalter, T.N., et al. (2012) Late Toxicity Rates Following Definitive Radiotherapy for Prostate Cancer. Canadian Journal of Urology, 19, 6373-6380.
Peeters, S.T.H., Heemsbergen, W.D., Koper, P.C.M., et al. (2006) Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy with 78 Gy. Journal of Clinical Oncology, 24, 1990-1996. https://doi.org/10.1200/JCO.2005.05.2530
Pollack, A., Zagars, G.K., Starkschall, G., et al. (2002) Prostate Cancer Radiation Dose Response: Results of the M.D. Anderson Phase III Randomized Trial. International Journal of Radiation Oncology, Biology, Physics, 53, 1097-1105. https://doi.org/10.1016/S0360-3016(02)02829-8
Cahlon, O., Zelefsky, M.J., Shippy, A., et al. (2008) Ultra-High Dose (86.4 Gy) IMRT for Localized Prostate Cancer: Toxicity and Biochemical Outcomes. International Journal of Radiation Oncology, Biology, Physics, 71, 330-337. https://doi.org/10.1016/j.ijrobp.2007.10.004
Viani, G.A., Stefano, E.J., Afonso, S.L., et al. (2009) Higher-Than-Conventional Radiation Doses in Localized Prostate Cancer Treatment: A Meta-Analysis of Randomized, Controlled Trials. International Journal of Radiation Oncology, Biology, Physics, 74, 1405-1418. https://doi.org/10.1016/j.ijrobp.2008.10.091
Dearnaley, D.P., Sydes, M.R., Langley, R.E., et al. (2007) The Early Toxicity of Escalated Versus Standard Dose Conformal Radiotherapy with Neo-Adjuvant Androgen Suppression for Patients with Localised Prostate Cancer: Results from the MRC RT01 Trial (ISRCTN47772397). Journal of Clinical Oncology, 83, 31-41. https://doi.org/10.1016/j.radonc.2007.02.014
Daskivich, T.J., Chamie, K., Kwan, L., et al. (2011) Overtreatment of Men with Low-Risk Prostate Cancer and Significant Comorbidity. Cancer, 117, 2058-2066. https://doi.org/10.1002/cncr.25751
Zietman, A.L., DeSilvio, M.L., Slater, J.D., et al. (2005) Comparison of Conventionaldose Vs High-Dose Conformal Radiation Therapy in Clinically Localized Adenocarcinoma of the Prostate: A Randomized Controlled Trial. Journal of the American Medical Association, 294, 1233-1239. https://doi.org/10.1001/jama.294.10.1233
Pollack, A., Zagars, G.K., Smith, L.G., et al. (2000) Preliminary Results of A Randomized Radiotherapy Dose-Escalation Study Comparing 70 Gy with 78 Gy for Prostate Cancer. Journal of Clinical Oncology, 18, 3904-3911. https://doi.org/10.1200/JCO.2000.18.23.3904
Saracino, B., Petrongari, M.G., Marziet, S., et al. (2014) Intensity-Modulated Pelvic Radiation Therapy and Simultaneous Integrated Boost to the Prostate Area in Patients with High-Risk Prostate Cancer: A Preliminary Report of Disease Control. Cancer Medicine, 3, 1313–1321. https://doi.org/10.1002/cam4.278
Michalski, J.M., Yan, Y., Watkins-Bruner, D., et al. (2013) Preliminary Toxicity Analysis of 3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy on the High-Dose Arm of the Radiation Therapy Oncology Group 0126 Prostate Cancer Trial. International Journal of Radiation Oncology, Biology, Physics, 87, 932-938. https://doi.org/10.1016/j.ijrobp.2013.07.041
Arcangeli, S., Saracino, B., Petrongari, M.G., et al. (2007) Analysis of Toxicity in Patients with High Risk Prostate Cancer Treated with Intensity-Modulated Pelvic Radiation Therapy and Simultaneous Integrated Dose Escalation to Prostate Area. Radiotherapy and Oncology, 84, 148-155. https://doi.org/10.1016/j.radonc.2007.06.011
Spratt, D.E., Zumsteg, Z.S., Zelefsky, M.J., et al. (2014) Comparison of High-Dose (86.4 Gy) IMRT Vs Combined Brachytherapy plus IMRT for Intermediate-Risk Prostate Cancer. BJU International, 114, 360-367. https://doi.org/10.1111/bju.12514
Wortel, R.C., Incrocci, L., Pos, F.J., et al. (2015) Acute Toxicity After Image-Guided Intensity Modulated Radiation Therapy Compared to 3D Conformal Radiation Therapy in Prostate Cancer Patients. International Journal of Radiation Oncology, Biology, Physics, 91, 737-744. https://doi.org/10.1016/j.ijrobp.2014.12.017
Volker, R.A., Nour, M. Hammoud, et al. (2016) Image-Guided Intensity-Modulated Radiotherapy of Prostate Cancer Analysis of Interfractional Errors and Acute Toxicity. Strahlentherapie und Onkologie, 192, 109-117. https://doi.org/10.1007/s00066-015-0919-y
David, S., Pat, C., El-Gayed, A., et al. (2010) Planning Target Volume Margins for Prostate Radio Therapy Using Daily Electronic Portal Imaging and Implanted Fiducial Markers. Radiation Oncology Journal, 5, 52. https://doi.org/10.1186/1748-717X-5-52